Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 8Colorectal Neoplasms 8Colonic Neoplasms 4Stomach Neoplasms 3Thrombocytopenia 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Inoperable Esophageal Cancer Stage I-III 1Hepatecellular Carcinoma 1Fruquintinib 1Esophageal Squamous Cell Carcinoma 1Advanced Metastatic Colorectal Cancer 1Advanced Gastric Cancer 1Advanced Colorectal Carcinoma 1Advanced Colorectal Cancer 1

Interventions

Oxaliplatin 3Cetuximab 3Capecitabine 3Irinotecan 2trifluridine tipiracil drug combination 1surufatinib 1regorafenib 1raltitrexed 1plocabulin 1nimotuzumab 1irinotecan sucrosofate 1endostar protein 1durvalumab 1defactinib 1Panitumumab 1N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Colorectal Cancer × raltitrexed × Clear all
NCT03126071 2021-08-30

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Jiangsu Cancer Institute & Hospital

Phase 2 Unknown
100 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡